Adicet Bio Inc.
(ACET)
undefined
undefined%
At close: undefined
1.00
2.20%
After-hours Jan 03, 2025, 05:54 PM EST
Company Description
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases.
The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients.
Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma.
The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors.
Adicet Bio, Inc. is based in Boston, Massachusetts.
Adicet Bio Inc.
| Country | United States |
| IPO Date | Jan 26, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 143 |
| CEO | Chen Schor BA, CPA, M.B.A. |
Contact Details
Address: 200 Clarendon Street Boston, Massachusetts United States | |
| Website | https://www.adicetbio.com |
Stock Details
| Ticker Symbol | ACET |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001720580 |
| CUSIP Number | 007002108 |
| ISIN Number | US0070021086 |
| Employer ID | 81-3305277 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Chen Schor BA, CPA, M.B.A. | Chief Executive Officer, President & Director |
| Brian Nicholas Harvey | Chief Financial Officer |
| Dr. Donald Healey Ph.D. | Chief Technology Officer |
| Amy Locke | Chief Human Resource Officer |
| Dr. Aya Jakobovits Ph.D. | Founder & Independent Director |
| Dr. Blake Aftab Ph.D. | Senior Vice President & Chief Scientific Officer |
| Dr. Francesco Galimi M.D., Ph.D. | Chief Medical Officer & Senior Vice President |
| Dr. Nancy L. Boman M.D., Ph.D. | Senior Vice President & Chief Regulatory Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 19, 2024 | 8-K | Current Report |
| Nov 27, 2024 | 8-K | Current Report |
| Nov 18, 2024 | 8-K | Current Report |
| Nov 15, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 06, 2024 | 10-Q | Quarterly Report |